Core Viewpoint - The company Jiukang Bio has a current stock price of 13.88 yuan, with a rolling PE ratio of 16.49, which is the lowest in the past 15 days, and a total market capitalization of 8.166 billion yuan [1]. Company Summary - Jiukang Bio specializes in the research, production, and sales of biochemical diagnostics, blood coagulation testing, blood type testing, and tumor pathology diagnostics [1]. - The main products include in vitro diagnostic reagents, in vitro testing instruments, instrument leasing, inspection services, laboratory assistance, and other businesses [1]. - The company was recognized as a "National Enterprise Technology Center" on February 22, 2023, as part of the 29th batch of newly recognized national enterprise technology centers [1]. Financial Performance - For the first quarter of 2025, Jiukang Bio reported an operating income of 320 million yuan, a year-on-year decrease of 18.81%, and a net profit of 83.2575 million yuan, down 30.99% year-on-year, with a gross profit margin of 80.84% [1]. Industry Comparison - The average PE ratio for the medical device industry is 50.80, with a median of 36.71, placing Jiukang Bio at the 39th position within the industry [1][2]. - The company has a total of 8 institutional holders, including 7 funds, with a total holding of 131.7025 million shares valued at 2.06 billion yuan [1].

Group 1 - China Energy Construction won a major coal-fired power project with a bid amount of approximately 14.586 billion yuan, involving six 660 MW supercritical coal-fired generating units and supporting environmental facilities, with a total construction period of about 36.5 months [1] - Taiji Industry plans to repurchase company shares with a total amount not less than 1 billion yuan and not exceeding 1.2 billion yuan, with a maximum repurchase price of 10.38 yuan per share [1] - Youxun Technology won a project from State Grid with a bid amount of approximately 176 million yuan, accounting for 17.44% of the company's audited revenue for 2024 [2] Group 2 - Daili New Materials established an investment fund with a total subscribed capital of 163.3 million yuan, with Daili contributing 10 million yuan, accounting for 6.12% of the fund [4] - Wanyi Technology received a government subsidy of 2.3475 million yuan, which has been confirmed and classified according to relevant accounting standards [6] - Anke Biotech received a drug registration certificate for Acetate Atosiban Injection, which is used for treating preterm labor [7] Group 3 - Renfu Pharmaceutical received a drug registration certificate for Progesterone Soft Capsules, which are used to treat functional disorders caused by progesterone deficiency [9] - Linyang Energy is a recommended candidate for a major contract with State Grid, with a total expected bid amount of approximately 165 million yuan [11] - Hongtian Technology plans to invest 200 million to 300 million yuan to establish a wholly-owned subsidiary in Gansu Province [28] Group 4 - Hunan Xiang Electric received a total of 40 million yuan in government subsidies, which accounts for 16.07% of the company's audited net profit for 2024 [44] - Nengke Technology plans to repurchase shares with a total amount not less than 10 million yuan and not exceeding 20 million yuan, with a maximum repurchase price of 43.00 yuan per share [46] - Xiamen XGMA received 10 million yuan in historical debt repayment, which is expected to increase the company's net profit for 2025 by 3.186 million yuan [48]

| 证券代码：300406 | 证券简称：九强生物 公告编号：2025-044 | | --- | --- | | 债券代码：123150 | 债券简称：九强转债 | 上述产品医疗器械注册证的取得，丰富了公司产品类别，有利于增强公 司的核心竞争力，对公司未来发展具有正面影响，但对近期的生产经营和业 绩不会产生重大影响，敬请投资者注意风险。 特此公告。 北京九强生物技术股份有限公司 董事会 北京九强生物技术股份有限公司 关于取得医疗器械注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 北京九强生物技术股份有限公司（以下简称"公司"）于近日收到北京 市药品监督管理局颁发的《医疗器械注册证》，具体情况如下： | 序号 | 产品名称 | | 注册证编号 | | 注册 类别 | | | | 注册证有效期 | | | | 预期用途 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | 二氧化碳质控品 | | 京 械 注 202 ...

Group 1 - The core viewpoint of the article highlights the financial performance and market position of Jiukang Biological Technology Co., Ltd., indicating a significant decline in revenue and net profit in the first quarter of 2025 compared to the previous year [1] - Jiukang Biological's stock closed at 13.57 yuan, with a rolling price-to-earnings (PE) ratio of 16.12 times, and a total market capitalization of 7.984 billion yuan [1] - The company ranks 40th in the medical device industry, which has an average PE ratio of 49.51 times and a median of 36.17 times [1][2] Group 2 - As of the first quarter of 2025, eight institutions hold shares in Jiukang Biological, with a total of 131.7025 million shares valued at 2.06 billion yuan [1] - The company's main business includes research, production, and sales of biochemical diagnostics, blood coagulation testing, blood type testing, and tumor pathology diagnostics [1] - Jiukang Biological was recognized as a "National Enterprise Technology Center" in February 2023, reflecting its commitment to technological advancement [1] Group 3 - The latest financial results show that Jiukang Biological achieved an operating income of 320 million yuan, a year-on-year decrease of 18.81%, and a net profit of 83.2575 million yuan, down 30.99% year-on-year, with a gross profit margin of 80.84% [1]

中国经济网北京5月19日讯 九强生物（300406）(300406.SZ)近日发布关于持股5%以上股东、董事减持 股份预披露公告显示，公司于近日收到持股5%以上股东、董事长邹左军，持股5%以上股东、董事刘 希，持股5%以上股东、董事罗爱平，持股5%以上股东、董事孙小林分别出具的《股份减持计划告知 函》。 持有九强生物股份（600201）39,280,659股（占公司有表决权股份比例为6.72%，"公司有表决权股份"为 截至2025年5月15日收盘时总股本剔除公司回购专用账户中的股份数量，下同）的大股东、董事长邹左 军计划自公告披露之日起十五个交易日后的三个月内以大宗交易方式减持公司股份，计划减持数量不超 过5,160,405股（占公司有表决权股份比例的0.88%）。 持有公司股份67,013,676股（占公司有表决权股份比例为11.46%）的大股东、董事刘希计划自公告披露 之日起十五个交易日后的三个月内以大宗交易方式减持公司股份，计划减持数量不超过8,803,766股（占 公司有表决权股份比例的1.51%）。 持有公司股份56,977,777股（占公司有表决权股份比例为9.74%）的大股东、董事罗爱平计划自公 ...

Group 1 - The core viewpoint of the article is that shareholders of Jiukang Bio plan to reduce their holdings by no more than 4.8% of the company's shares [1] - The article mentions that the Hui Lian convertible bond will undergo a downward adjustment [1] - The board of directors of Puli will propose a downward adjustment for its bonds [1] Group 2 - The article states that Yong 22 convertible bond, Kesi convertible bond, and Jingke convertible bond will not undergo downward adjustments [1] - The article encourages readers to follow the WeChat account of Jisilu for more information [2]

2024年1至12月份，九强生物的营业收入构成为：医疗卫生占比100.0%。 （文章来源：每日经济新闻） 九强生物（SZ 300406，收盘价：13.49元）5月16日晚间发布公告称，持有北京九强生物技术股份有限 公司股份约3928万股（占公司有表决权股份比例为6.72%，"公司有表决权股份"为截至2025年5月15日收 盘时总股本剔除公司回购专用账户中的股份数量，下同）的大股东、董事长邹左军先生计划自本公告披 露之日起十五个交易日后的三个月内以大宗交易方式减持公司股份，计划减持数量不超过约516万股 （占公司有表决权股份比例的0.88%）。持有公司股份约6701万股（占公司有表决权股份比例为 11.46%）的大股东、董事刘希先生计划自本公告披露之日起十五个交易日后的三个月内以大宗交易方 式减持公司股份，计划减持数量不超过约880万股（占公司有表决权股份比例的1.51%）。持有公司股 份约5698万股（占公司有表决权股份比例为9.74%）的大股东、董事罗爱平先生计划自本公告披露之日 起十五个交易日后的三个月内以大宗交易方式减持公司股份，计划减持数量不超过约749万股（占公司 有表决权股份比例的1.28%）。持 ...

证券代码：300406 证券简称：九强生物 公告编号：2025-043 债券代码：123150 债券简称：九强转债 北京九强生物技术股份有限公司 关于持股5%以上股东、董事减持股份预披露公告 持股 5%以上股东、董事长邹左军先生，持股 5%以上股东、董事刘希先生，持股 5%以上股东、董事罗爱平先生，持股 5%以上股东、董事孙小林先生保证向本公司提供 的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 1、持有北京九强生物技术股份有限公司(以下简称"公司"或"九强生 物")股份39,280,659股（占公司有表决权股份比例为6.72%，"公司有表决 权股份"为截至2025年5月15日收盘时总股本剔除公司回购专用账户中的股 份数量，下同）的大股东、董事长邹左军先生计划自本公告披露之日起十五 个交易日后的三个月内以大宗交易方式减持本公司股份，计划减持数量不超 过5,160,405股（占公司有表决权股份比例的0.88%）。 2、持有公司股份67,013,676股（占公司有表决权股份比例为11.46%）的 大股东、董事刘希先生 ...

第五届董事会第十六次会议决议公告 证券代码：300406 证券简称：九强生物 公告编号：2025-041 债券代码：123150 债券简称：九强转债 北京九强生物技术股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 北京九强生物技术股份有限公司(以下简称"公司")第五届董事会 第十六次会议（以下简称"本次会议"）于 2025 年 5 月 9 日在公司会 议室以现场表决和通讯表决相结合的方式召开。本次会议已于 2024 年 5 月 9 日以电话、电子邮件等方式通知全体董事。公司全体董事均同意 豁免本次董事会会议通知时限要求。会议由公司董事长邹左军主持，公 司副董事长梁红军，董事刘希、罗爱平、孙小林、王小亚、陈永宏、杨 建平、叶军出席了会议。公司监事及高级管理人员列席了本次会议。 本次会议的通知、召集、召开和表决符合《中华人民共和国公司法》 等相关法律法规和《公司章程》的有关规定。 二、董事会会议审议情况 经与会董事充分讨论与审议，会议形成以下决议： 1、审议通过《关于不向下修正"九强转债"转股价格的议案》 本次触发转股价格向下 ...

北京九强生物技术股份有限公司 关于不向下修正"九强转债"转股价格的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： | 证券代码：300406 | 证券简称：九强生物 | 公告编号：2025-042 | | --- | --- | --- | | 债券代码：123150 | 债券简称：九强转债 | | 经深交所同意，公司 113,900.00 万元可转换公司债券于 2022 年 7 月 20 日 起在深交所挂牌交易，债券简称"九强转债"，债券代码"123150"。 （三）可转换公司债券转股期限 "九强转债"转股期自可转债发行结束之日（2022 年 7 月 6 日）满 6 个月 后的第一个交易日（2023 年 1 月 6 日）起至可转债到期日（2028 年 6 月 29 日） 止。 1、截至 2025 年 5 月 9 日，北京九强生物技术股份有限公司（以下简称"公 司"）股票价格已出现连续三十个交易日中至少有十五个交易日的收盘价低于当 期转股价格的 85%，因实施 2024 年年度权益分派，"九强转债"的转股价格由 17.35 元/股下调至 16 ...